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Background: Pre-workout supplements (PWS) have increased in popularity among athletic populations for their
purported ergogenic benefits. Most PWS contain a “proprietary blend” of several ingredients, such as caffeine,
beta-alanine, and nitrate in undisclosed dosages. Currently, little research exists on the safety and potential side
effects of chronic consumption of PWS, and even less so involving female populations. Therefore, the purpose of
the present study was to examine the safety of consuming a dose-escalated PWS over a 28-day period among
active adult females.
Methods: 34 recreationally active, adult females (27.1 ± 5.4 years, 165.2 ± 5.7 cm, 68.2 ± 16.0 kg) participated in this
study. Participants were randomly assigned to consume either 1 (G1) or 2 (G2) servings of a PWS daily or remain
unsupplemented (CRL) for a period of 28 days. All were instructed to maintain their habitual dietary and exercise
routines for the duration of the study. Fasting blood samples, as well as resting blood pressure and heart rate, were
taken prior to and following the supplementation period. Samples were analyzed for hematological and clinical
chemistry panels, including lipids.
Results: Significant (p < 0.05) group by time interactions were present for absolute monocytes (CRL −0.10 ± 0.10;
G1 + 0.03 ± 0.13; G2 + 0.01 ± 0.12×10E3/uL), MCH (CRL −0.13 ± 0.46; G1 + 0.36 ± 0.52; G2 -0.19 ± 0.39 pg), creatinine
(CRL 0.00 ± 0.05; G1 -0.06 ± 0.13; G2 -0.14 ± 0.08 mg/dL), eGFR (CRL −0.69 ± 5.97; G1 + 6.10 ± 15.89; G2 + 14.63 ±
7.11 mL/min/1.73), and total cholesterol (CRL −2.44 ± 13.63; G1 + 14.40 ± 27.32; G2 -10.38 ± 15.39 mg/dL). Each of
these variables remained within the accepted physiological range. No other variables had significant interactions.
Conclusion: The present study confirms the hypothesis that a PWS containing caffeine, beta-alanine, and nitrate
will not cause abnormal changes in hematological markers or resting vital signs among adult females. Although
there were statistically significant (p < 0.05) group by time interactions for absolute monocytes, MCH, creatinine,
eGFR, and total cholesterol, all of the results remained well within accepted physiological ranges and were not
clinically significant. In sum, it appears as though daily supplementation with up to 2 servings of the PWS under
investigation, over an interval of 28 days, did not adversely affect markers of clinical safety among active adult females.
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Nutrient timing refers to the methodical, timed ingestion
of carbohydrate, protein, fat and other dietary supple-
ments either before, during, or after physical activity [1].
Supplementation during the period immediately preced-
ing physical activity has become an increasingly popular* Correspondence: jordan@musclepharm.com
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alike as a means of improving performance [2]. In re-
sponse to this trend, manufacturers have developed pre-
workout supplements (PWS), which typically combine
caffeine with any number of purported ergogenic sub-
stances, such as beta-alanine, nitrate, and amino acids.
As the number of PWS available on the market grows,
each containing their own “proprietary blend” of active
ingredients, it must be determined which, if any, are safe
for chronic consumption. This becomes particularly im-
portant as concerns have arisen over the concept ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Drug Administration does not monitor the amounts of
ingredients used in these blends or the accuracy of prod-
uct labeling by manufacturers [2].
Caffeine is one of the most commonly found ingredi-
ents in PWS. An extensive amount of scientific literature
exists on the ergogenic properties of caffeine [3-5]. Ac-
cording to the International Society of Sports Nutrition’s
position stand on caffeine and performance, it is most
effective when consumed in low to moderate doses,
about 3–6 mg per kilogram bodyweight, 30–60 minutes
prior to exercise [4]. Caffeine has been shown to im-
prove performance in endurance events and time-trials,
improve cognitive function and alertness, and delay the
onset of fatigue during exhaustive exercise [3,5]. More-
over, caffeine anhydrous, which is frequently used in PWS,
has been shown to have greater ergogenic effects than caf-
feine ingested in the form of coffee, tea, or cola [4].
Beta-alanine (BA), another common ingredient in
PWS, is an amino acid which serves as a rate-limiting
precursor to carnosine in skeletal muscle [6]. Carnosine’s
suggested mechanism of action may be to buffer hydro-
gen ions during exercise, thereby influencing intracellu-
lar muscle pH, and ultimately increasing work capacity
[7]. In a recent review of the literature by Quesnele et al.
[8], the authors concluded that although there is evi-
dence to suggest that BA supplementation enhances ath-
letic performance, the safety of its use remains unclear,
and there is a general under-reporting of its side effects
in the literature.
Despite the existing literature pertaining to individual
ingredients contained in PWS and the growing number
of studies that address multi-ingredient PWS specifically,
we are unaware of any published reports examining the
safety of PWS in a solely female population. Therefore,
the purpose of the present study was to examine the
safety of chronic consumption of a PWS over a 28 day
period among active adult females. We hypothesized
that daily PWS supplementation would not produce ab-
normal changes in hematological or metabolic safety
markers or resting vital signs.
Methods
Experimental design
In a dose-escalated, simple randomized design, 34 sub-
jects were randomly assigned to control (CRL, n = 16;
27.1 ± 5.9 y, 166.2 ± 4.0 cm, 65.2 ± 12.9 kg), 1 serving (G1,
n = 10; 24.9 ± 3.9 y, 164.7 ± 5.8 cm, 72.4 ± 23.3 kg), or 2
serving (G2, n = 8; 29.6 ± 5.8 y, 163.8 ± 8.8 cm, 69.0 ±
11.6 kg) groups via random number generation by the
investigators and asked to remain unsupplemented, or
consume either 1 or 2 servings, respectively, of a pre-
workout formula (Fitmiss Ignite™, MusclePharm Corp.,
Denver, CO) every day for 28 days. The pre-workoutformula contained 1 g of carbohydrate, 23 mg of Cal-
cium, and 5,700 mg of a proprietary blend consisting of
beta-alanine, choline bitartrate, L-tyrosine, glycine, tau-
rine, L-carnitine, beetroot extract, hawthorn berry pow-
der, agmatine sulfate, caffeine anhydrous, and huperzine
A. The supplement was analyzed by a third party (Euro-
fins Supplement Analysis Center, Petaluma, CA) and
verified to contain all of the ingredients on the label.
Subjects were instructed to consume 1–2 level scoop(s)
of the supplement with 12 oz water per scoop either
30 minutes prior to exercise or at the same time of day
on rest days. Compliance was monitored using supple-
ment consumption logs, as well as by weighing supple-
ment containers before and after the supplementation
period. A total of 38 subjects were initially recruited for
this study. From G1, one subject discontinued the study
due to noncompliance, and from G2, three subjects dis-
continued due to noncompliance. The CRL group con-
tained more total participants, as CRL group data was
added from a previously conducted study which fea-
tured a design exactly identical to the present study.
Participants completed the study with an average sup-
plementation compliance of 94.6% for G1 and 100% for
G2. Blood draws were taken prior to and following the
supplementation period. Approval for the human sub-
ject protocol was obtained from MusclePharm Sports
Science Institute’s IRB, and subjects were provided with
written informed consent documents prior to participa-
tion in the study.
Participants
34 recreationally active female adults (27.1 ± 5.4 years,
165 ± 5.7 cm, 68.2 ± 16.0 kg) participated in the study.
Recreationally active was defined as habitually participat-
ing in moderate to vigorous physical activity on three or
more days a week for a duration of thirty minutes or
more. Subjects were required to be non-smokers, free of
any disease or disorder which may have produced con-
founding effects, and have abstained from taking any
other pre-workout supplements for one month prior to
the beginning of the study. Exclusion criteria included
having a significant history or current presence of a
treated condition, such as high blood pressure
(≥140 mmHg systolic and/or ≥90 mmHg diastolic),
tachyarrhythmia, or heart, kidney, or liver disease, or
any contraindication to physical activity. Also excluded
from the study were participants whose willingness or
ability to comply with the study protocol was uncertain.
Eligibility was determined upon evaluation of pre-
participation health history, exercise, and supplementa-
tion screening questionnaires. A caffeine usage question-
naire was given as part of the pre-participating screening
process, with average self-reported caffeine consumption
prior to study being 131 mg/day for G1 and 269 mg/day
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ual dietary and exercise routines, and to not take any
additional supplements during their participation in the
study.Measurements
All measurements were taken prior to and following the
28-day supplementation period in a quiet, temperature
controlled private office. Upon arrival at the office, sub-
jects were instructed to remain seated quietly for 15 mi-
nutes before resting vital signs, height, and weight were
taken. Subjects then submitted a blood sample in the
fasted state. All blood draws were performed in the
morning to prevent diurnal variations by a trained phle-
botomist via venipuncture. Samples were analyzed for
comprehensive metabolic panels, complete blood counts
and lipid profiles by an external laboratory (Laboratory
Corporation of America, Denver, CO). Variables re-
corded from blood analysis consisted of white blood cell
count (WBC), red blood cell count (RBC), hemoglobin,
hematocrit, mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH), mean corpuscular
hemoglobin concentration (MCHC), red blood cell dis-
tribution width (RDW), platelets (absolute), neutrophils
(percent and absolute), lymphocytes (percent and abso-
lute), monocytes (percent and absolute), eosinophils
(percent and absolute), basophils (percent and absolute),
serum glucose, blood urea nitrogen (BUN), creatinine,
estimated glomerular filtration rate (eGFR), BUN:cre-
atinine, sodium, potassium, chloride, carbon dioxide, cal-
cium, protein, albumin, globulin, albumin:globulin,
bilirubin, alkaline phosphatase, aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), total choles-
terol, triglycerides, high density lipoprotein (HDL)
cholesterol, and low density lipoprotein (LDL) choles-
terol. Inter-test reliability results from 12 men and
women measured up to one week apart at the aforemen-
tioned laboratory resulted in no significant differences
for any of the variables noted above from day-to-day
(p > 0.05) and an average inter-test Coefficient of Vari-
ation (CV) of 6.9%.Statistical analyses
Data was analyzed using a 3×2 repeated measures
ANOVA model for all group, time, and group by time in-
teractions. A Bonferroni post-hoc analysis was used to lo-
cate differences. Shapiro-Wilk tests were used to
determine normality of the data. The Minimal Difference
(MD) needed to be considered real was determined using
the method previously described by Weir [9]. Data are
presented as means ± standard deviation. All data were
analyzed using Statistica software (Statsoft, Version 10).Results
Significant group by time interactions were present for ab-
solute monocytes (p < 0.05), wherein CRL decreased rela-
tive to G1 and G2. Absolute monocytes had a normal
distribution at baseline (p = 0.07), yet the distribution was
positively skewed (p < 0.05) after the supplementation
period. Significant group by time interactions were ob-
served with MCH (p < 0.05), with G1 increasing relative to
CRL and G2. Significant group by time interactions were
detected for creatinine (p < 0.05), with G2 decreasing rela-
tive to CRL. Significant group by time interactions were
noted for eGFR (p < 0.05), with G2 increasing relative to
control. Significant group by time interactions were also
present for total cholesterol (p < 0.05), G1 increasing
relative to CRL and G2. Total cholesterol was positively
skewed at baseline (p < 0.05), and at post-supplementation,
it became normally distributed (p = 0.99). MCH and eGFR
were normally distributed (p > 0.05) at both time points,
and creatinine was positively skewed (p < 0.05) at both time
points. All variables remained within the accepted physio-
logical range at baseline and post supplementation. No
other variables had significant group by time interactions.
Data are presented in Additional file 1 as means ± standard
deviation. Tolerability data collected from participants
reported no serious adverse events. The most common re-
ported side effects were a tingling sensation (n = 6), itchi-
ness (n = 2), and nausea (n = 2). Other reported side effects
included dizziness, lightheadedness, dry mouth, headache,
a burning sensation, and diarrhea (all n = 1). Most of these
effects occurred within the first several days of supplemen-
tation and subsided over time.
Discussion
The results of the present study suggest that daily sup-
plementation with the PWS under investigation does not
appear to cause any abnormal changes in hematological
and clinical chemistry/metabolic safety markers or rest-
ing vital signs in female subjects. While significant group
by time interactions (p < 0.05) were observed for abso-
lute monocytes, MCH, creatinine, eGFR, and total chol-
esterol, all group values remained well within the
accepted physiological range and were not clinically sig-
nificant. While remaining within range, unusual effects
were observed between groups. For instance, the CRL
group decreased relative to G1 and G2 for absolute
monocytes, and for MCH and total cholesterol, G1 in-
creased relative to both CRL and G2. Similar to total
cholesterol, although not reaching significance (p > 0.05),
both LDL and HDL increased in G1 but decreased in
G2 over time. These findings are somewhat discrepant,
since intuitively, one would think that if a lower dose in-
creases a given parameter compared to control, then a
higher dose should amplify this effect. This, however,
was not the case. Such results suggest a natural variation
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lated to supplementation. Additionally, the control
group (n = 16) was larger than either of the experimental
groups (G1, n = 10; G2, n = 8), so individual variations
within the experimental groups had greater impact on
the group mean values.
Variables that were significantly different at the group
level were evaluated at the individual level to determine
clinical significance. Analysis of clinical significance at
the individual level was conducted using the MD statis-
tic, which calculates the magnitude of the inter-test dif-
ference (between baseline and post-supplementation)
needed to be exceeded in order for a single measure-
ment to be considered real, as described by Weir [9].
The MD is calculated using the standard error of meas-
urement (SEM), which is considered an absolute index
of the reliability of a given test/measurement, not rela-
tive to the characteristics of the sample or population
from which values were obtained. Unlike other reliability
measures, such as the CV, the SEM and thus the MD,
are not affected by between-subject variability [9]. If a
subject’s measured values exceeded the MD, the change
was considered a true change. Clinical significance at the
individual level was reached when a score that exceeded
the MD crossed the upper or lower limits of the ac-
cepted physiological range for each variable. For creatin-
ine, this occurred in three subjects, one from G1 and
two from G2, wherein values decreased pre to post,
bringing them within the clinical reference range. For
total cholesterol, changes observed in two subjects from
G1 and one from G2 exceeded the MD. Specifically, the
two subjects from G1 increased over time, moving from
within range to out of range, while the subject from G2
decreased pre to post, entering the accepted reference
range. Also worth noting is the fact that three individ-
uals from the CRL group experienced changes in total
cholesterol values that both exceeded the MD and
moved in or out of range. In this case, one subject in-
creased over time to leave the accepted range, one
started outside of the range and remained out of range,
and one decreased pre to post, entering back into range.
All subjects remained within 3 standard deviations of
the mean and exceeded the MD. Collectively, individual
analysis supports the present hypothesis and also sup-
ports the notion of intra-subject diurnal variability. Fur-
thermore, absolute monocytes and total cholesterol were
distributed differently pre to post, increasing the prob-
ability for a type 1 statistical error [10].
These findings generally agree with previous literature.
Aside from the research pertaining to PWS effects on
performance [11-16], only a limited number of studies
have also examined the clinical safety of PWS. Kedia
et al. [17] looked at the effects of a multi-ingredient
PWS containing caffeine, betaine, and dendrobiumextract on body composition, performance measures,
and hematological markers of clinical safety in healthy,
young men and women undergoing concurrent resist-
ance training for six weeks. While the investigators did
not see an improvement in objective assessments of ex-
ercise performance or body composition with supple-
mentation, they found the PWS to be well tolerated with
no significant changes in clinical laboratory safety
markers at the end of six weeks.
Similarly, Shelmadine et al. [18] examined the effects
of 28 days consuming a commercially available PWS,
NO-Shotgun®, combined with heavy resistance exercise
on body composition, muscle strength and mass, myofi-
brillar protein content, markers of satellite cell activa-
tion, and clinical safety markers in male subjects. They
found no negative side effects or abnormal impact on
clinical safety markers after 28 days of supplementation.
In a follow up study of the same nature, this time with a
post-workout supplement added (NO-Synthesize®), Spil-
lane et al. [19] again found no detrimental effects on
clinical safety markers following 28 days supplementa-
tion and resistance training with NO-Shotgun®.
Farney et al. [20] investigated hemodynamic and
hematological effects of two supplements containing caf-
feine and 1,3- dimethylamylamine (a constituent of gera-
nium) after 14 days of supplementation in men and
women, and found only a significant change in blood
glucose for one of the supplements (Jack3d™) over this
time period. A follow up to this study conducted by
Whitehead et al. [21] supplemented with the same prod-
uct containing caffeine and 1,3- dimethylamylamine
(Jack3d™) over a 10-week period in healthy males and
also found it did not negatively impact hematological
markers of health when consumed daily.
Kendall et al. [22] investigated the safety and efficacy
of a PWS containing caffeine, creatine, beta-alanine,
amino acids and B-vitamins in recreationally trained,
college-age men over an identical period of 28 days. In
that study, no adverse effects were observed for renal or
hepatic clinical blood markers or resting vital signs. Re-
searchers concluded that PWS with similar ingredients
in similar doses should be safe for ingestion periods up
to 28 days in healthy males. More recently, Joy et al. [23]
found that supplementation with a PWS containing caf-
feine, nitrate, and amino acids in healthy, recreationally
active men and women was apparently safe when taken
within recommended dosage guidelines for 28 days.
To our knowledge, this is the first study assessing the
clinical safety of a PWS in an all-female population.
Female-specific recommendations for sports nutrition
and supplementation is an area that warrants more
attention. A review article by Volek, Forsythe, and Kraemer
[24], for instance, identifies the subtle, yet important differ-
ences in exercise metabolism between male and female
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cluding nutrient timing and supplement use, should be tai-
lored to meet the sex-specific needs of female athletes. In
another review article addressing gender differences in
sports nutrition, Tarnopolsky [25] similarly concluded that
future studies in nutrition and metabolism should exam-
ine and consider sex differences in response to supple-
mentation and exercise. It therefore seems prudent for
future research to continue to address sports nutrition
supplementation in females to evaluate both safety and ef-
ficacy in this population as compared to males.
Limitations
The present study included a short duration supplemen-
tation period and small sample size. Future studies
should examine the effects of supplementation for lon-
ger than 28 days among more subjects, especially given
the fact that statistically significant interactions did take
place over time in the present study. Again, while none
of the significant variables left the accepted physiological
range, the possibility that these could be the beginnings
of adverse trends cannot be ruled out. This leaves long-
term safety of PWS supplementation, at least greater
than 28 days, still open to question.
Conclusion
This study supports the hypothesis that a PWS contain-
ing caffeine, beta-alanine, and nitrate will not cause ab-
normal changes in hematological or clinical chemistry/
metabolic markers, or resting vital signs among recre-
ationally active females. Although there were statistically
significant (p < 0.05) group by time interactions for abso-
lute monocytes, MCH, creatinine, eGFR, and total chol-
esterol, all of the results remained well within accepted
physiological ranges and were not clinically significant.
In sum, it appears as though daily supplementation with
up to 2 servings of the PWS used in this investigation,
over a period of 28 days, had no adverse impact on
markers of clinical safety among active adult females.
Additional file
Additional file 1: Data collected pre and post supplementation.
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